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’ INTRODUCTION AND PRESENTATION OF THE
ETHICAL ISSUE
Breast cancer (BC) is the most common type of cancer in
Brazil; it was responsible for 15,593 deaths in 2015, and an
estimated 59,700 new cases were diagnosed in 2018 (1). BC in
Brazil has some peculiarities when compared to other coun-
tries; 35 to 41.1% of all cases are diagnosed among patients
younger than 50 years old, and most of the operable cases are
diagnosed in later stages (53.5% stage 2 and 23.2% stage 3)
(2), despite the opportunistic mammographic screening
program (MSP) supported by the national government. The
screening model adopted in Brazil recommends a mammo-
gram every two years for women between the ages of 50 and
69 (3). However, the frequent diagnosis of BC in women at
younger ages in Brazil leads to the claim that over 40% of the
women diagnosed with cancer were not eligible for the MSP
to begin with. The late stage at diagnosis, on the other hand,
leads to the hypothesis that the current screening program is
either not effective or individuals do not have proper access
to it. Additionally, BC mortality in Brazil has been increasing
in the last decades (4). Together, these factors pose an ethical
issue, as investing valuable resources in an ineffective pro-
gram negatively impacts the whole society and, therefore,
smarter resource allocation schemes should be implemented
to address this issue. In this editorial, we will dispute, from a
utilitarian approach, the usefulness of the current MSP recom-
mendation in a country with great inequalities among its
regions and will also discuss an alternative to breast cancer
screening from a Rawlsian perspective.
’ RECOMMENDATION
In light of the ineffectiveness of the current Brazilian BC
screening program in reducing mortality, we recommend
resource reallocation to improve access to care and to establish
a rapid pathway for diagnosis and treatment based on the
hierarchical flow proposed by Migowski et al. (5). This algo-
rithm proposes three distinct actions: increase educational
activities in primary healthcare units to raise awareness and
disseminate information about BC; offer shared decision-
making regarding mammographic screening to asymptomatic
patients between 50 and 69 years old in their primary care
visit with a nurse or physician; and promote priority care,
without the need to schedule appointments, for symptomatic
patients, in which patients with suspected breast cancer
would have priority referral to breast diagnostic services for
diagnostic confirmation.
’ SUPPORTING EVIDENCE AND ETHICAL THEORIES
Brazil is a developing country with a population of 209.3
million inhabitants that has large economic and social
disparities between its 5 regions (6). The country also
presents inequalities in the distribution of health and human
resources, with significant variation in the number of cancer
care hospitals and physicians across its regions (4). There are
also inequalities in health outcomes in the country that might
be explained by the duality of its health system. Healthcare
in Brazil can be provided via the public system (Sistema
Único de Saúde – SUS) or via the private system (based on
health insurance plans or self-paying individuals). This sys-
tem duality is somewhat perverse as it perpetuates the idea
that a small part of the population can afford state-of-the-art
private healthcare, whereas the majority, approximately 71%
of the population, has to rely solely on the SUS. When we
compare patients from these two settings, we can see a stri-
king difference; the majority of patients in the private setting
are diagnosed with early stage disease, while most patients
on SUS are diagnosed with locally advanced BC, clearly
denoting that the lack of access is the main obstacle to early
detection (7). The perversity comes mostly from the fact that
the SUS has long waiting lines for referrals; for example, the
mean time between BC presentation and biopsy in patients
on SUS is between 75-185 days, which might impact progno-
sis (7); even after diagnosis, there are still waiting lines for
treatment (the average time for radiation therapy is approxi-
mately 113.4 days (8)). In the private system, for comparison
purposes, a patient can obtain a mammogram, have a biopsy
and start treatment in less than 30 days. In addition, SUS
does not cover all cancer drugs that are readily available in
the private setting. Taken together, all these factors lead to aDOI: 10.6061/clinics/2019/e1573
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great difference in health outcomes, favoring patients from
the private setting, as demonstrated by Lee et al. (9). A large
body of evidence corroborates this argument, supporting
that the existence of healthcare access barriers and socio-
economic inequalities are the main reasons for late-stage
diagnosis, rather than a lack of screening (9-12).
In a country with the above-demonstrated inequalities, the
recommendation proposed in this paper is aligned with
Rawls’ two principles of justice: the first is that each person
has the right to equal basic rights and liberties, and the
second is that social and economic inequalities are acceptable
as long as they benefit the least advantaged members of society
(13). The first part of the recommendation, which promotes
educational sessions, is a clear example of Rawls’ first principle
of justice. The promotion of education to raise awareness of
an increasingly important health issue in the least educated
part of the population provides equal access to a basic right
(education itself). The second part of the recommendation
can be justified by Rawls’ second principle of justice. By
providing easy and fast access to patients with symptomatic
breast conditions, removing the necessity to schedule appoint-
ments and prioritizing referrals, we are allocating resources to
remove barriers to accessing the healthcare system, with the
objective of reducing delays in diagnosis and treatment, and
therefore, reducing inequalities and favoring the least advan-
taged members of society that do not have access to private
healthcare. Although the recommendation favors the least
advantaged, it does not infringe on the rights of other indivi-
duals, as asymptomatic patients would still have the right to
undergo mammographic screening after counseling with their
primary care physicians. Furthermore, the proposed recom-
mendation removes age boundaries, promoting equal access
to the breast cancer care continuum to women younger than
50 years old, an unmet need of the current adopted model
since these patients, who account for up to 41.1% of all BC
cases (2), do not fulfill the age requirement for the govern-
ment’s MSP.
One might argue that the resource reallocation proposed
here will decrease the odds of early diagnosis in the most-
favored, well-educated portion of the population. We can
refute this claim by quoting Rawls himself and acknowl-
edging that "All social primary goods are to be distributed
equally unless an unequal distribution of any of all of these
goods is to the advantage of the least favored" (13). More-
over, the most favored, well-educated part of the population
would not be forbidden to have screening exams; we can
argue that the wealthy population can utilize their private
insurance and conduct the screening on their own without
the need for public resources.
However, let’s hypothesize for a moment that Brazil does
not have any barriers to accessing healthcare. Would the
current MSP then be the ideal intervention in the breast
cancer care continuum? The answer would still be no. The
evidence supporting the MSP is not unanimous, and large
recently published clinical trials have failed to demonstrate a
reduction in BC mortality from screening (14,15). Even if
those studies turned out to show a BC mortality reduction,
would their results be applicable to Brazil’s reality? Again,
the answer would be no. Those studies were carried out in
countries with high human development indexes (an index
that assesses the health, education and economy of countries)
and in the setting of organized screening programs. Brazil
not only has a much lower human development index
but also promotes opportunistic screening due to a weak
organizational structure, instead of the organized modalities
evaluated in the referenced studies. In this way, the data
from those studies should not be applied in Brazil to justify
the adoption of an MSP. A local manuscript recently pub-
lished by Vale et al suggested that the opportunistic screen-
ing program used in Brazil promoted downstaging in BC in
the most developed state in the country; however, it did not
show BC mortality reduction, which is the ultimate goal of
any cancer screening program (16). Those are strong argu-
ments to support, from a utilitarian perspective, that screen-
ing by itself is not an ideal intervention in Brazil as there is
not enough evidence to support that it provides maximal
benefit to society. Moreover, mammographic screening has
harmful potential, having its own associated mortality and
morbidity risks, including breast radiation, anxiety, unneces-
sary biopsies (due to false-positive mammogram results) and
risks involved in diagnostic surgery (17).
One might argue, however, that having a mammogram
once a year is not a costly intervention. However, mammo-
graphic screening of an asymptomatic population is indeed a
costly intervention, as it does not include only the cost of the
initial mammogram. Ten percent of patients get called back
for additional imaging, and 10% of those will have a biopsy.
Only 30% of all biopsies will be positive, meaning that 70%
of biopsied patients will receive a biopsy for normal breast
tissue (18). With such high levels of false-positive results,
screening in this setting cannot be justified from a utilitarian
point of view.
’ CONCLUSION
When we weigh the benefits and harms of the current MSP
in Brazil, in the context of increasing breast cancer mortality
in recent decades, it is very difficult to justify the resources
needed to promote this intervention in the breast cancer care
continuum from a utilitarian perspective. An alternative
approach promoting easy and fast healthcare access for
symptomatic patients and relegating the MSP to a secondary
role favors a vulnerable portion of the Brazilian population
who rely solely on the public system. In this way, allocating
more resources to favor the least advantaged members of
society is not only ethically acceptable, but also a way of
promoting justice.
’ REFERENCES
1. INCA. Breast Cancer statistics. 2019 Available from: https://www.inca.
gov.br/tipos-de-cancer/cancer-de-mama.
2. Simon SD, Bines J, Werutsky G, Nunes JS, Pacheco FC, Segalla JG, et al.
Characteristics and prognosis of stage I-III breast cancer subtypes in
Brazil: The AMAZONA retrospective cohort study. Breast. 2019;44:113-9.
https://doi.org/10.1016/j.breast.2019.01.008
3. INCA. Diretrizes para a detecc¸ão precoce do câncer de mama no Brasil
2015 2015.
4. da Mota Almeida Peroni F, Lindelow M, Oliveira De Souza D, Sjoblom M.
Realizing the right to health in Brazil’s Unified Health System through the
lens of breast and cervical cancer. Int J Equity Health. 2019;18(1):39.
https://doi.org/10.1186/s12939-019-0938-x
5. Migowski A, Dias MBK, Nadanovsky P, Silva GAE, Sant’Ana DR, Stein
AT. Guidelines for early detection of breast cancer in Brazil. III - Chal-
lenges for implementation. Cad Saude Publica. 2018;34(6):e00046317.
6. World Bank Group. Brazil - systematic country diagnostic. 2016. Available
from: http://documents.worldbank.org/curated/pt/239741467991959045/
pdf/106569-SCD-P151691-PUBLIC-non-board-version.pdf
7. Werutsky G, Nunes P, Barrios C. Locally advanced breast cancer in Brazil:
current status and future perspectives. Ecancermedicalscience. 2019;13:
895. https://doi.org/10.3332/ecancer.2019.895
8. (TCU) TdCDU. Relatório de Auditoria Operacional: Política Nacional de
Atenc¸ão Oncológica. In: Governo. 2011. Available from: https://portal.
2
Ethics and breast cancer screening in Brazil




9. Lee BL, Liedke PE, Barrios CH, Simon SD, Finkelstein DM, Goss PE.
Breast cancer in Brazil: present status and future goals. Lancet Oncol.
2012;13(3):e95-e102. https://doi.org/10.1016/S1470-2045(11)70323-0
10. Vieira RADC, Formenton A, Bertolini SR. Breast cancer screening in
Brazil. Barriers related to the health system. Rev Assoc Med Bras. 2017;
63(5):466-74. https://doi.org/10.1590/1806-9282.63.05.466
11. Dos-Santos-Silva I, De Stavola BL, Renna NL Junior, Nogueira MC,
Aquino EML, Bustamante-Teixeira MT, et al. Ethnoracial and social trends
in breast cancer staging at diagnosis in Brazil, 2001-14: a case only ana-
lysis. Lancet Glob Health. 2019;7(6):e784-e97. https://doi.org/10.1016/
S2214-109X(19)30151-2
12. Cabral ALLV, Giatti L, Martinez-Hernaez A, Cherchiglia ML. Inequality in
breast cancer care in a Brazilian capital city: a comparative analysis of
narratives. Int J Equity Health. 2019;18(1):88. https://doi.org/10.1186/
s12939-019-0989-z
13. Rawls J. A theory of justice. Rev. ed. Cambridge, Mass.: Belknap Press of
Harvard University Press; 1999. xxii, 538 p.
14. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L.
Effectiveness of Breast Cancer Screening: Systematic Review and Meta-
analysis to Update the 2009 U.S. Preventive Services Task Force Recom-
mendation. Ann Intern Med. 2016;164(4):244-55. https://doi.org/10.73
26/M15-0969
15. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year
follow-up for breast cancer incidence and mortality of the Canadian
National Breast Screening Study: randomised screening trial. BMJ.
2014;348:g366. https://doi.org/10.1136/bmj.g366
16. Vale DB, Filho CC, Shinzato JY, Spreafico FS, Basu P, Zeferino LC.
Downstaging in opportunistic breast cancer screening in Brazil: a tem-
poral trend analysis. BMC Cancer. 2019;19(1):432. https://doi.org/
10.1186/s12885-019-5647-8
17. Nelson HD, Pappas M, Cantor A, Griffin J, Daeges M, Humphrey L.
Harms of Breast Cancer Screening: Systematic Review to Update the 2009
U.S. Preventive Services Task Force Recommendation. Ann Intern Med.
2016;164(4):256-67. https://doi.org/10.7326/M15-0970
18. Vanderburgh D. Breast cancer screening. Politics Life Sci. 2018;37(1):
135-40. https://doi.org/10.1017/pls.2018.3
3
CLINICS 2019;74:e1573 Ethics and breast cancer screening in Brazil
Gonc¸alves R et al.
